AnthonySteinMD

Oncology • Duarte, CA

Physician

Join to view full profile

Dr. Stein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Stein's full profile

Already have an account?

Office
1500 Duarte Rd
Duarte, CA 91010
Phone+1 626-256-4673

Education & Training

City of Hope National Medical CenterFellowship, Hematology and Medical Oncology, 1985 - 1987
UPMC Medical EducationResidency, Internal Medicine, 1982 - 1984
University of Cape Town Faculty of MedicineClass of 1978

Certifications & Licensure

CA State Medical License 1984 - 2026
PA State Medical License 1983 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) Start of enrollment: 2005 Jun 01
Completed
Phase 2
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 1994 Sep 01
Completed
Phase 2
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer Start of enrollment: 2000 Feb 29
Active, not recruiting
Phase 2
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R Start of enrollment: 2000 Feb 08
Active, not recruiting
Phase 2
Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer Start of enrollment: 2007 Jun 11
Terminated
Phase 1, Phase 2
Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Start of enrollment: 2008 Mar 04
Active, not recruiting
Phase 1, Phase 2
Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes Start of enrollment: 2007 Jul 01
Completed
Phase 1
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm Start of enrollment: 2010 Aug 01
Completed
Phase 2
Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome Start of enrollment: 2013 Jan 01
Terminated
Phase 1, Phase 2
A Safety Study of SGN-CD33A in AML Patients Start of enrollment: 2013 Jul 01
Completed
Phase 1
Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML Start of enrollment: 2014 May 12
Recruiting
Phase 2
SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Start of enrollment: 2014 Sep 01
Completed
Phase 1, Phase 2
Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2018 Mar 19
Recruiting
Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Start of enrollment: 2017 Jun 26
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax Start of enrollment: 2022 Jul 29
Active, not recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

14 citations
Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL.
Ibrahim Aldoss, Dongyun Yang, Vanina Tomasian, Sally Mokhtari, Ryan Jackson
Blood Advances. 2022-09-13
6 citations
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Phila...
Ibrahim Aldoss, Michelle Afkhami, Dongyun Yang, Zhaohui Gu, Sally Mokhtari
American Journal of Hematology. 2023-06-01
1221 citations
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop M. Kantarjian, Anthony S. Stein, Nicola Gökbuget, Adele K. Fielding, Andre C. Schuh
The New England Journal of Medicine. 2017-03-01

Journal Articles

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML
Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood

Abstracts/Posters

Targeting MiR-126 Blocks Progression of Myelodysplastic Syndrome and Transformation into Acute Myeloid Leukemia
Anthony Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosid...
Anthony Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...
Anthony Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
Anthony Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE¬ (Bispecific T-Cell Engager) in Patients with R...
Anthony Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy
Anthony Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Downregulation of Mir-142 Promotes Leukemia Growth in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): A Possible Novel Therapeutic Target?
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in AdultsClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Cytokine Gene Polymorphisms Are Associated with Disease Response to Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Changing Game Plan for Acute Lymphocytic Leukemia: Emerging Treatment Options and Progressive Approaches to Patient Care
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

Innate Pharma to Present Results from a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients with Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022November 4th, 2022
City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual ConferenceDecember 8th, 2020
Cellworks Singula™ Predicts Personalized Therapy Responses for AML and MDS Patients with Higher Accuracy Than Physician Prescribed TreatmentsMay 14th, 2020
Join now to see all